Extended Data Fig. 6: Combination of molnupiravir or remdesivir with Pyrazofurin but not AVN944 is synergistically antiviral in vitro.
From: Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
a, BLISS analysis in Calu3 cells with molnupiravir (EIDD-2801) or remdesivir in combination with pyrazofurin. Data are presented as mean values of Excess over BLISS. (n = 4 independent biological replicates). The statistical significance was determined by a one-sample t-test (* p < 5x10−2; **p < 10−3). b, Anti-SARS2 activity of molnupiravir, remdesivir, and AVN944 as single agents. Data are presented as mean ± SD. c, Anti-SARS2 activity of molnupiravir or remdesivir in combination with a single concentration of AVN944. d, Two-dimensional representation of dose response interaction matrix for percent of control of infection. Data are presented as mean ± SD (n = 10 for EIDD-2801, n = 6 for remdesivir for independent biological replicates).
